CD8A and neoplasm: Although the clinical activity of the combination of pembrolizumab and 5-azacytidine was modest in the treatment for chemotherapy-refractory mCRC, the expression of several immune gene sets and the density of CD8+ tumor-infiltrating lymphocytes was increased in CRC tissues from patients after the treatment [42].